| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
| Targets |
β-lactam
Cefonicid sodium exerts its antibacterial activity by binding to and inactivating penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs disrupts peptidoglycan formation, leading to bacterial cell lysis. Cefonicid sodium has a high affinity for PBP 1a in Escherichia coli K-12 (strain KN-126). |
|---|---|
| ln Vitro |
Cefonicid sodium is a broad-spectrum cephalosporin antibiotic effective against a range of Gram-negative bacteria. It is effective against E. coli, Klebsiella, Enterobacter, and Citrobacter. The compound also shows activity against Staphylococcus and Streptococcus species. In addition to its antibacterial effects, cefonicid sodium has been shown to inhibit the carnitine/carnitine antiport when added both externally and internally to proteoliposomes.
|
| ln Vivo |
Cefonicid sodium is a broad-spectrum cephalosporin antibiotic used in research studies. It is effective in treating infections caused by Staphylococcus and Streptococcus species. In research settings, cefonicid sodium is utilized for studies in pharmacokinetics, antibiotic resistance, and bacterial infection models. The compound's ability to inhibit the carnitine/carnitine antiport has also been studied in vitro.
|
| Enzyme Assay |
Cefonicid sodium's activity is assessed using standard in vitro microbiological susceptibility testing methods. Minimum inhibitory concentration (MIC) determinations are performed against various bacterial strains. The compound's binding affinity to penicillin-binding proteins (PBPs) can be evaluated using competitive binding assays with radiolabeled penicillin. The inhibition of the carnitine/carnitine antiport can be studied using proteoliposome-based transport assays.
|
| Cell Assay |
Cellular assays for cefonicid sodium are conducted using standard microbiological techniques with bacterial cultures. The compound's antibacterial activity is evaluated by determining the minimum inhibitory concentration (MIC) against various bacterial strains, including E. coli, Klebsiella, Enterobacter, and Citrobacter. Bacterial growth inhibition is assessed by measuring optical density or by counting colony-forming units. The compound's effects on bacterial cell wall synthesis can also be studied.
|
| Animal Protocol |
In vivo animal model experiments for cefonicid sodium would involve administration to animal models of infection to evaluate its efficacy. The compound is used in research studies on pharmacokinetics, antibiotic resistance, and bacterial infection models. Animal models of infections caused by Staphylococcus and Streptococcus species could be used. Such studies are essential for understanding the compound's in vivo behavior and therapeutic potential.
|
| ADME/Pharmacokinetics |
Cefonicid sodium is administered parenterally. Specific pharmacokinetic data is not extensively detailed in the available literature. As a second-generation cephalosporin, it is expected to have a half-life that supports once-daily dosing. The compound is widely distributed in body tissues and fluids. It is primarily excreted by the kidneys.
|
| Toxicity/Toxicokinetics |
Cefonicid sodium is generally well-tolerated as a cephalosporin antibiotic. Common adverse effects associated with cephalosporins include gastrointestinal disturbances, hypersensitivity reactions (particularly in patients with penicillin allergy), and local reactions at the injection site. The compound is intended for research use only.
|
| References | |
| Additional Infomation |
Cefonicid sodium is an organosoil salt containing a Cefonicid (2-) group. Cefonicid sodium is the sodium salt form of Cefonicid, a semi-synthetic second-generation cephalosporin with antibacterial activity. Cefonicid binds to and inactivates penicillin-binding protein (PBP) located on the inner membrane of bacterial cell walls. PBP is an enzyme involved in the final stages of bacterial cell wall assembly and in remodeling the cell wall during growth and division. Inactivation of PBP interferes with the cross-linking of peptidoglycan chains, which is essential for maintaining the strength and rigidity of bacterial cell walls. This leads to weakening of the bacterial cell wall and ultimately cell lysis. Cefonicid sodium is a second-generation cephalosporin that can be administered intravenously or intramuscularly. Its bactericidal action stems from the inhibition of cell wall synthesis. It is used to treat urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections. See also: Cefonicid (containing the active ingredient).
Cefonicid Sodium (CAS# 61270-78-8) is a broad-spectrum, second-generation cephalosporin antibiotic. It is the sodium salt form of cefonicid and is administered parenterally. The compound inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). It is effective against E. coli, Klebsiella, Enterobacter, Citrobacter, Staphylococcus, and Streptococcus species. It is utilized in research studies on pharmacokinetics, antibiotic resistance, and bacterial infection models. |
| Molecular Formula |
C18H16N6NA2O8S3
|
|---|---|
| Molecular Weight |
586.53
|
| Exact Mass |
585.998
|
| Elemental Analysis |
C, 36.86; H, 2.75; N, 14.33; Na, 7.84; O, 21.82; S, 16.40
|
| CAS # |
61270-78-8
|
| Related CAS # |
190181-58-9 (disodium);61270-78-8 (sodium);61270-58-4 (free);71420-79-6 (monosodium);
|
| PubChem CID |
43593
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
> 160ºC
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
37
|
| Complexity |
980
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
S1C([H])([H])C(C([H])([H])SC2=NN=NN2C([H])([H])S(=O)(=O)[O-])=C(C(=O)[O-])N2C([C@]([H])([C@@]12[H])N([H])C([C@@]([H])(C1C([H])=C([H])C([H])=C([H])C=1[H])O[H])=O)=O.[Na+].[Na+]
|
| InChi Key |
NAXFZVGOZUWLEP-RFXDPDBWSA-L
|
| InChi Code |
InChI=1S/C18H18N6O8S3.2Na/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32;;/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32);;/q;2*+1/p-2/t11-,13-,16-;;/m1../s1
|
| Chemical Name |
disodium;(6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfonatomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
|
| Synonyms |
Cefonicid Sodium; Monocid; Cefonicid disodium salt; SK&F D-75073-Z2; UNII-F74MFL78A1; CHEBI:3492; SKF-75073-2; SKF750732; Cefonicid, Sodium; Monocid;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~213.12 mM)
H2O : ~100 mg/mL (~170.49 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.26 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.26 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (4.26 mM) Solubility in Formulation 5: 100 mg/mL (170.49 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7049 mL | 8.5247 mL | 17.0494 mL | |
| 5 mM | 0.3410 mL | 1.7049 mL | 3.4099 mL | |
| 10 mM | 0.1705 mL | 0.8525 mL | 1.7049 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
